MedTrace Logo

Premenstrual Hormonal and Affective State Evaluation (PHASE) Project

NCT03862469 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2025-04-24

Study results available
· View outcomes & findings →

Summary

PHASE is designed to evaluate neuroactive hormone trajectories across the menstrual cycle and endocrine, autonomic, and subjective responses to psychosocial stress in women suffering from severe PMS (i.e., premenstrual dysphoric disorder).

Conditions

  • Premenstrual Dysphoric Disorder

Interventions

PROCEDURE

Individualized laboratory test

Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Ajna Hamidovic, PharmD, MS · University of Illinois at Chicago

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03862469 on ClinicalTrials.gov